

**NCT West Community Retreat – 05.02.2025**  
**“Create Innovative Trials in Cancer Research”**

Veranstaltungsort: CIO Köln, Kerpener Str. 62/Gebäude 70, 50937 Köln

12:00	<b>Registrierung und Mittagessen</b>
13:00	<b>Begrüßung</b> M. Hallek und M. Schuler <span style="float: right;">Seminarraum 3/4</span>
13:05	<b>Vorstellung des NCT West im One NCT &amp; des OCT<sup>2</sup> Programms</b> M. Hallek und M. Schuler <span style="float: right;">Seminarraum 3/4</span>
13:30	<b>Evaluationsprozess für des NCT IIT Portfolios - Erfahrungsberichte</b> M. Wiesweg und M. Butler <span style="float: right;">Seminarraum 3/4</span>
14:00	<b>Interaktive Sitzung 1</b> <u><b>Session A – Seminarraum 1:</b></u> <ul style="list-style-type: none"> <li>• Eleonora Ramadori: <i>FO-HAIC: Intraarterial chemotherapy in progressed hepatocellular carcinoma (HCC); Aim: OS extension of patients with high risk HCC through intraarterial chemotherapy (HAIC-HOLFOX)</i></li> <li>• Thomas Schmidt: <i>SOFTER - Study on Optimizing Fibroblast Modulation for Treatment Enhancement in Resectable Esophageal Adenocarcinoma</i></li> </ul> <u><b>Session B – Seminarraum 3/4:</b></u> <ul style="list-style-type: none"> <li>• Bastian von Tresckow: <i>A phase II prospective, multicenter trial of glofitamab, polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone (Glofit-Pola-R-CHP) for PET-guided chemotherapy deescalation in low-risk Large B Cell Lymphoma (LBCL)</i></li> <li>• Christian Pallasch: <i>A Phase Ib/IIa trial for evaluation of oral Benfo-oxythyamin (B-OT) in Combination with CD20-directed chemoimmunotherapy in B cell lymphoma</i></li> </ul>
15:15	<b>Kaffeepause</b>
15:45	<b>Interaktive Sitzung 2</b> <u><b>Session A – Seminarraum 1:</b></u> <ul style="list-style-type: none"> <li>• Björn Scheffler &amp; Laurel Rauschenbach: <i>An NCT study on the prognostic and predictive value of the cranial bone marrow in patients with newly diagnosed glioblastoma</i></li> <li>• Volker Neuschmelting: <i>TAILOR – STimulated RAman HIstoLogy cOntrolled Resection in adult-type low grade glioma</i></li> </ul> <u><b>Session B – Seminarraum 3/4:</b></u> <ul style="list-style-type: none"> <li>• Paul Bröckelmann: <i>JAK-STAR: JAK2 Inhibition for Steroid-Resistant Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors</i></li> <li>• Florin-Andrei Taran: <i>Acceptance of Robotic-assisted versus Open Interval Debulking Surgery for Ovarian Cancer after Neo-adjuvant Chemotherapy: a Randomized Feasibility Study</i></li> </ul>
17:00	<b>Keynote Lecture</b> Prof. Roland Schwarz: <i>AI for Cancer Evolution: From Inference to Prediction</i> <span style="float: right;">Seminarraum 3/4</span>
17:30	<b>Abschluss &amp; Zusammenfassung</b> Plenardiskussion <span style="float: right;">Seminarraum 3/4</span>
18:00	<b>Verabschiedung und Get-Together</b>